Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
Quintana, Angela (Hospital Universitari Vall d'Hebron)
Saini, Kamal S. (Addenbrookes Hospital(Cambridge, Regne Unit))
Vidal Boixader, Laura (Fortrea, Inc. (Durham, Estats Units d'Amèrica))
Peg, Vicente (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Slebe, Juan Felipe (Oncoclínicas & Co (Jersey City, Brasil))
Loibl, Sibylle (German Breast Group (Neu-Isenburg, Alemanya))
Curigliano, Giuseppe (University of Milano (Milà, Itàlia))
Schmid, Peter (Barts Cancer Institute (Londres, Regne Unit))
Cortés Castán, Javier (IOB Madrid. Hospital Beata Maria Ana (Madrid))

Data:	2024
Resum:	Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient's prognosis.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Window of opportunity ; Immune checkpoint inhibitors ; Triple-negative breast cancer ; Tumor-infiltrating lymphocytes ; PD-L1
Publicat a:	ESMO open, Vol. 9 Núm. 10 (October 2024) , ISSN 2059-7029

DOI: 10.1016/j.esmoop.2024.103713
PMID: 39357122

18 p, 447.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats